Should All Patients Receive Statins to Reduce Cancer Risk after Heart Transplantation?
The study by Frölich et al1 in this issue of Circulation adds to the body of evidence that Statins as a class of drugs have effects which reduce the chance of cancer initiation and progression, recapitulating findings showing reductions in cancer related mortality in statin users in other major malignancies such as breast and prostate cancer.2,3 The authors are explicit in recognising the flaws inherent in interpreting the data from their single centre case series but non-the-less, the size of their series is substantial, patients have been followed carefully for long and clinically relevant time periods and the reduction in cancer incidence, from 34 to 13% is impressive. Furthermore, there is an overall reduction in the cancer related death rate and this seems to be even greater in its extent in those patients receiving prolonged therapy. In the absence of another explanation the evidence for these findings being attributable to statins is alluring but is this truly a statin related effect and if it is, how is the therapy working?(SELECT FULL TEXT TO CONTINUE)
- Received June 22, 2012.
- Accepted June 25, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited